Bruker today announces another significant milestone in its collaborator’s efforts to map the long-term risk of disease related to SARS-CoV-2 infection using nuclear magnetic resonance (NMR) spectroscopy. Researchers from the Australian National Phenome Center (ANPC) have recently published results from a study that demonstrate the use of NMR to measure the increased cardiovascular risk in COVID-19 and post-acute COVID-19 syndrome (PACS) patients for research use only. Professor Jeremy Nicholson, Director of the ANPC, commented: “In our search for diagnostic markers for COVID19 and related pathologies we have uncovered new types of marker for cardiovascular disease risk- the supramolecular phospholipid composite signals. We now know that these metrics are of wider significance in assessing long term cardiovascular disease and can be readily measured using rapid NMR methods.
Read more about this news here.
